Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetics in liver disease.

D D Breimer

    Pharmaceutisch Weekblad. Scientific Edition
    |April 24, 1987
    PubMed
    Summary

    Drug pharmacokinetics are altered in liver disease, affecting drug clearance and availability differently for high- and low-clearance drugs. Standard liver function tests cannot predict these changes in drug disposition.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Site specific rectal drug administration in man with an osmotic system: influence on "first-pass" elimination of lidocaine.

    Pharmaceutical research·2013
    Same author

    Avoidance of "first-pass" elimination of rectally administered propranolol in relation to the site of absorption in rats.

    Pharmaceutical research·2013
    Same author

    Correlation between in vivo antipyrine metabolite formation and theophylline metabolism in rats.

    Pharmaceutical research·2013
    Same author

    The metabolic formation of N-acetyl-S-2-hydroxyethyl-L-cysteine from tetradeutero-1,2-dibromoethane. relative importance of oxidation and glutathione conjugation in vivo.

    Biochemical pharmacology·2010
    Same author

    P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.

    Pharmaceutical research·2001
    Same author

    Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2001

    Area of Science:

    • Pharmacology
    • Hepatology
    • Drug Metabolism

    Background:

    • Liver disease significantly impacts drug disposition, necessitating an understanding of pharmacokinetic alterations.
    • Hepatic dysfunction affects drug clearance, distribution, and metabolism, influencing therapeutic outcomes.
    • General pharmacokinetic principles are crucial for predicting drug behavior in patients with liver conditions.

    Purpose of the Study:

    • To review general pharmacokinetic principles relevant to altered drug disposition in liver disease.
    • To differentiate the impact of hepatic dysfunction on high- and low-clearance drugs.
    • To highlight the limitations of conventional liver function tests in predicting drug disposition changes.

    Main Methods:

    • Review of general pharmacokinetic principles.
    • Differentiation of drug clearance (high vs. low).
    • Analysis of drug administration routes (intravenous vs. oral).

    Main Results:

    • High-clearance drugs show reduced systemic clearance (IV) due to decreased liver blood flow and increased availability (oral) due to reduced enzyme activity/shunting.
    • Low-clearance drugs are sensitive to reduced enzyme activity and protein binding.
    • Oxidative reactions are more affected than conjugation reactions in liver disease.
    • Significant inter-patient variability in drug kinetics is observed.
    • Conventional liver function tests are ineffective for predicting altered drug disposition.

    Conclusions:

    • Drug disposition is significantly altered in liver disease, with distinct effects on high- and low-clearance drugs.
    • Hepatic dysfunction impacts drug metabolism pathways differently, with oxidative reactions being more vulnerable.
    • Predicting altered drug pharmacokinetics in liver disease requires understanding specific drug properties and patient variability, not relying on standard liver function tests.

    Related Experiment Videos